MDT

101.97

+0.97%↑

A

135.82

+0.7%↑

VEEV

224.09

+1.05%↑

HQY

84.93

+0.94%↑

NEOG

9.81

0%↓

MDT

101.97

+0.97%↑

A

135.82

+0.7%↑

VEEV

224.09

+1.05%↑

HQY

84.93

+0.94%↑

NEOG

9.81

0%↓

MDT

101.97

+0.97%↑

A

135.82

+0.7%↑

VEEV

224.09

+1.05%↑

HQY

84.93

+0.94%↑

NEOG

9.81

0%↓

MDT

101.97

+0.97%↑

A

135.82

+0.7%↑

VEEV

224.09

+1.05%↑

HQY

84.93

+0.94%↑

NEOG

9.81

0%↓

MDT

101.97

+0.97%↑

A

135.82

+0.7%↑

VEEV

224.09

+1.05%↑

HQY

84.93

+0.94%↑

NEOG

9.81

0%↓

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

220.7 0.48

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

217.07

Massimo

220.63

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+0.88% upside

Dividendi

By Dow Jones

Utili prossimi

18 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2B

11B

Apertura precedente

220.22

Chiusura precedente

220.7

Notizie sul Sentiment di mercato

By Acuity

50%

50%

145 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 gen 2026, 23:49 UTC

Discorsi di Mercato

Oil Falls on Possible Technical Correction -- Market Talk

25 gen 2026, 23:43 UTC

Discorsi di Mercato

Correction to Gold Rises Above $5000/oz Market Talk

25 gen 2026, 23:43 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

25 gen 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Fall After Yen's Sharp Rebound -- Market Talk

25 gen 2026, 23:36 UTC

Discorsi di Mercato

Gold Rises Above $5,000/oz for First Time Amid Geopolitical Tensions -- Market Talk

25 gen 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

25 gen 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Companies Had Been Discussing Roughly $30B Deal -- WSJ

25 gen 2026, 19:30 UTC

Acquisizioni, Fusioni, Takeovers

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

24 gen 2026, 09:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

24 gen 2026, 09:20 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

24 gen 2026, 09:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

24 gen 2026, 09:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

24 gen 2026, 06:18 UTC

Acquisizioni, Fusioni, Takeovers

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

23 gen 2026, 22:30 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

23 gen 2026, 22:30 UTC

Discorsi di Mercato

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

23 gen 2026, 22:03 UTC

Utili

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 gen 2026, 21:52 UTC

Utili
Acquisizioni, Fusioni, Takeovers

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

23 gen 2026, 21:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

23 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 gen 2026, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

23 gen 2026, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

23 gen 2026, 21:39 UTC

Utili

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

23 gen 2026, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

23 gen 2026, 21:12 UTC

Utili

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

23 gen 2026, 20:31 UTC

Utili

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

23 gen 2026, 20:12 UTC

Discorsi di Mercato

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

23 gen 2026, 20:07 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

23 gen 2026, 19:36 UTC

Discorsi di Mercato

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

23 gen 2026, 19:30 UTC

Discorsi di Mercato
Utili

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

23 gen 2026, 19:18 UTC

Discorsi di Mercato

Gold and Silver Step Up to More Records -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

0.88% in crescita

Previsioni per 12 mesi

Media 221.55 USD  0.88%

Alto 265 USD

Basso 170 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

9

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

145 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat